Johnson & Johnson Beats Q1 Estimates, Premarket Not Doing WellJohnson & Johnson (NYSE: NYSE:JNJ ) on Tuesday reported better-than-expected Q1 results and lifted its sales forecast for the full year.
Johnson & Johnson (NYSE: NYSE:JNJ ), together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the h
Key facts today
Johnson & Johnson will present TAR-200 study data for high-risk bladder cancer on April 26, showing a positive response rate after 12 months in cohort 2 and initial results from cohort 4.
12.88 T ARS
81.33 T ARS
About Johnson & Johnson
Sector
Industry
CEO
Joaquin Duato
Website
Headquarters
New Brunswick
Founded
1887
ISIN
ARDEUT110236
FIGI
BBG000C4WYM3
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas, such as immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular & metabolic diseases. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular & neurovascular, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.
Buy JNJ for Stable Gains Amid Earnings Optimism Next Week
- Key Insights: Johnson & Johnson demonstrated robust earnings performance with
an EPS of $2.77, surpassing consensus estimates and reinforcing its
defensive stock status. Its diverse portfolio and consistent ability to
execute in volatile markets make it a strong candidate for growth-oriente
Johnson & Johnson Wave Analysis – 18 April 2025
- Johnson & Johnson rising inside weekly price range
- Likely to test resistance level 165.60
Johnson & Johnson continues to rise in the primary upward impulse wave 3, which started earlier from the major support level 145.00 (lower border of the weekly sideways price range from 2023).
The up
Johnson & Johnson (JNJ) Shares Drop Over 7%Johnson & Johnson (JNJ) Shares Drop Over 7%
As the chart shows, Johnson & Johnson (JNJ) shares declined by approximately 7.6%, reaching their lowest level since late February. This marked one of the worst performances in the stock market yesterday.
Why Did JNJ Shares Fall?
Two major bearish fac
Cracks Appearing in J&J's Armor?Johnson & Johnson, a long-established leader in the global healthcare sector, confronts substantial challenges that raise significant questions about its future trajectory and stock valuation. Foremost among these is the persistent and massive litigation surrounding its talc-based baby powder. With
Johnson&Johnson: Rejected AgainJohnson&Johnson has now been rejected at the $168.75 resistance level for the second time, pulling back more noticeably in response. However, in our primary scenario, we still expect an imminent breakout above this level, which should allow the turquoise wave X to establish its high well above it. A
Johnson and Johnson Falling Off a Cliff. JNJA much larger ABCDE formation is complete, not pivoting back to gravity. There is confirmation with MIDAS cross of price action with supporting of RSX exiting OBOS area and VZO/Stoch duo being bearish divergent for some time now. The incoming stream could be a tumultous C Wave impulse to the bears,
See all ideas
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
US478160CS1
JOHNSON&JOHN 20/50Yield to maturity
7.28%
Maturity date
Sep 1, 2050
US478160CT9
JOHNSON&JOHN 20/60Yield to maturity
7.21%
Maturity date
Sep 1, 2060
US478160CR3
JOHNSON&JOHN 20/40Yield to maturity
6.55%
Maturity date
Sep 1, 2040
US478160CM4
JOHNSON & JOHNSON 17/48Yield to maturity
6.34%
Maturity date
Jan 15, 2048
JNJJ
JOHNSON & JOHNSON 17/47Yield to maturity
6.21%
Maturity date
Mar 3, 2047
US478160BV5
JOHNSON & JOHNSON 16/46Yield to maturity
6.17%
Maturity date
Mar 1, 2046
US478160CL6
JOHNSON & JOHNSON 17/38Yield to maturity
5.67%
Maturity date
Jan 15, 2038
US478160CX0
JOHNSON&JOHN 24/54Yield to maturity
5.63%
Maturity date
Jun 1, 2054
JNJ4077469
Johnson & Johnson 4.5% 05-DEC-2043Yield to maturity
5.62%
Maturity date
Dec 5, 2043
US478160CF9
JOHNSON & JOHNSON 17/37Yield to maturity
5.48%
Maturity date
Mar 3, 2037
JNJ.GT
Johnson & Johnson 4.5% 01-SEP-2040Yield to maturity
5.44%
Maturity date
Sep 1, 2040
See all JNJ bonds
Curated watchlists where JNJ is featured.